Monitoring T cells may allow prevention of type 1 diabetes
Scripps Research Institute | 07-19-2023
Scripps Research scientists have shown that analyzing a certain type of immune cell in the blood can help identify people at risk of developing type 1 diabetes, a life-threatening autoimmune disease. The new approach, if validated in further studies, could be used to select suitable patients for treatment that stops the autoimmune process—making type 1 diabetes a preventable condition.
In the study, which appeared in Science Translational Medicine, the researchers isolated T cells (a type of immune cell) from mouse and human blood samples. By analyzing the T cells that can cause type 1 diabetes, they were able to distinguish the at-risk patients who had active autoimmunity from those who had no significant autoimmunity—with 100% accuracy in a small sample.
“These findings represent a big step forward because they offer the possibility of catching this autoimmune process while there is still time to prevent or greatly delay diabetes,” says study senior author Luc Teyton, MD, PhD, professor in the Department of Immunology and Microbiology at Scripps Research.
The study’s first authors were graduate student Siddhartha Sharma and research assistants Josh Boyer and Xuqian Tan, all of the Teyton lab at the time of the study.
Type 1 diabetes occurs when the immune system destroys the insulin-producing “islet cells” of the pancreas. The autoimmune process that underlies type 1 diabetes can occur over years, with multiple starts and stops. Exactly how the process begins is not well understood, though it is known to involve genetic factors and may be triggered by routine viral infections. When it occurs, it usually does so in childhood or early adulthood, and requires lifelong insulin replacement. Researchers estimate that about two million people have type 1 diabetes in the U.S. alone.
In 2022, the U.S. Food & Drug Administration approved an immune-suppressing therapy that can protect islet cells and at least delay diabetes onset by months to years if given in the early stages of autoimmunity. However, doctors have not had a good method for identifying people who could benefit from such treatment. They have traditionally examined levels of anti-islet antibodies in patient blood samples, but this antibody response has not been a very accurate measure of autoimmune progression.
“Anti-islet antibody levels are poorly predictive at the individual level, and type 1 diabetes is fundamentally a T cell-driven disease,” Teyton says.
In the study, Teyton and his team constructed protein complexes to mimic the mix of immune proteins and insulin fragments that specialized T cells called CD4 T cells normally would recognize to initiate the autoimmune reaction. They used these constructs as bait to capture anti-insulin CD4 T cells in blood samples. They then analyzed the gene activity within the captured T cells, and expression of proteins on the cells, to gauge their state of activation.
In this way, they were able to develop a classification algorithm that correctly identified which at-risk patients, in a set of nine, had ongoing anti-islet autoimmunity.
Teyton now hopes to validate the CD4 T cell-based approach with a long-term study in a larger cohort of participants, comparing this approach to the traditional approach of quantifying anti-islet antibodies.
Teyton and his colleagues also are working to make the process of isolating and analyzing anti-islet T cells in blood samples more affordable and convenient, so that it can be used more easily in a clinical setting.
“If we can develop this into a useful method for identifying at-risk patients and tracking their autoimmunity status, we not only would have a way of getting the right people into treatment, but also would be able to monitor their disease progress and evaluate potential new preventive therapies,” Teyton says.
Materials provided by Scripps Research Institute. Content may be edited for clarity, style, and length.